Clinical Trial Update: Pembrolizumab Plus Neoadjuvant Chemotherapy for Locally Advanced EGJ Adenocarcinoma [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating pembrolizumab plus neoadjuvant chemotherapy for locally advanced esophagogastric junction adenocarcinoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Adenocarcinoma of Esophagogastric Junction

Drugs mentioned

• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: Tianjin Medical University Cancer Institute and Hospital | Conditions: Adenocarcinoma of Esophagogastric Junction, Neoadjuvant Chemotherapy | Phase 2 | Status: UNKNOWN